Under the collaboration, which is funded by a Wellcome Trust Seeding Drug Discovery award, Argenta will provide medicinal chemistry, computer-aided drug design and ADME/PK (absorption, distribution, metabolism and excretion/pharmacokinetic) services, along with its integrated drug discovery expertise, to help ANTABIO identify novel anti-bacterial agents and a development candidate that can be further stepped into clinical trials.
Argenta managing director Dr John Montana said the firm is delighted to announce the agreement with ANTABIO, which is the second SDDI-funded collaboration to be disclosed by the company in recent months.
"There is an urgent need for new anti-bacterial drugs and we look forward to working with ANTABIO to progress their compounds rapidly towards pre-clinical candidate nomination," Montana added.